First human trial aims to lengthen telomeres, offering hope for rare genetic diseases
NCT ID NCT06817590
Summary
This early-stage trial is testing whether a combination of two oral compounds (deoxycytidine and deoxythymidine) is safe for people with rare genetic disorders called telomere biology disorders. These disorders cause very short telomeres (protective caps on chromosomes), leading to bone marrow failure, lung disease, and other serious health problems. The study will enroll 36 patients aged 1-70 to take the medication three times daily for 24 weeks, monitoring for side effects and checking for changes in blood counts and lung function.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TELOMERE BIOLOGY DISORDERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Boston Childrens Hospital
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.